Proteomics company raises $128 Million in Series C financing


Proteomics company Alamar Biosciences closed $100 million in Series C financing with the second close of an additional $28 million expected to happen within the next 30 days.

This new capital brings Alamar’s total funding to date to nearly $250 million. The financing round was led by Sands Capital and included participation from new financial and strategic investors as well as existing major investors.

Concurrent with the financing, Ian Ratcliffe, Executive Managing Partner of Sands Capital, has joined the Company’s Board of Directors.

“Proteomics represents a dynamic and fast-growing market with significant opportunity for disruption as new platforms providing both higher sensitivity and multiplex capability are needed to accelerate proteomics research and translation,” said Ian Ratcliffe, Executive Managing Partner of Sands Capital.

Earlier this year, Alamar launched the ARGO HT System and the NULISAseq Inflammation Panel 250 for deep profiling of immune response.

In July 2022 the company announced a partnership with Abcam to further their understanding of the human proteome.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free